Vaccine against hepatitis B--18 months prevention in a high risk setting
The development of a vaccine against hepatitis B prepared with purified and inactivated HBs Ag is described. This vaccine has been applied in patients and staff members of haemodialysis centres. Safety and efficiency of the vaccine are very satisfactory. The response of patients to immunisation was...
Gespeichert in:
| Veröffentlicht in: | Medical microbiology and immunology 1978-11, Vol.166 (1-4), p.109-118 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 118 |
|---|---|
| container_issue | 1-4 |
| container_start_page | 109 |
| container_title | Medical microbiology and immunology |
| container_volume | 166 |
| creator | Maupas, P Goudeau, A Coursaget, P Drucker, J Bagros, P Baudin, S Geslin, N |
| description | The development of a vaccine against hepatitis B prepared with purified and inactivated HBs Ag is described. This vaccine has been applied in patients and staff members of haemodialysis centres. Safety and efficiency of the vaccine are very satisfactory. The response of patients to immunisation was significantly lower compared to the response of the staff members. None of the volunteers who had a primary response to immunisation developed signs of clinical or biological hepatitis. |
| doi_str_mv | 10.1007/BF02121140 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_74254787</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>74254787</sourcerecordid><originalsourceid>FETCH-LOGICAL-c281t-3f97338c83bc2969a62d517d66fd06577ac4e254fd3655496ffe551511f343353</originalsourceid><addsrcrecordid>eNpFkDtPwzAYRS3EqxQWZgZPDEgBf353pBWlSJVYgDVyHbsxNE6IXST-PUGtYLrLuWc4CF0CuQVC1N10TihQAE4O0Ag4owVoBodoRBghhRaan6KzlN4JASUpOUHHijKl2Qgt3oy1ITps1ibElHHtOpNDDglPi8GCmzbmOuGud18u5tBGHCI2uA7rGvchfeDkcg5xfY6OvNkkd7HfMXqdP7zMFsXy-fFpdr8sLNWQC-YnijFtNVtZOpETI2klQFVS-opIoZSx3FHBfcWkEHwivXdCgADwjDMm2Bhd77xd335uXcplE5J1m42Jrt2mUvHhrbQawJsdaPs2pd75sutDY_rvEkj5W638rzbAV3vrdtW46g_dZWI_WXtkaw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>74254787</pqid></control><display><type>article</type><title>Vaccine against hepatitis B--18 months prevention in a high risk setting</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Maupas, P ; Goudeau, A ; Coursaget, P ; Drucker, J ; Bagros, P ; Baudin, S ; Geslin, N</creator><creatorcontrib>Maupas, P ; Goudeau, A ; Coursaget, P ; Drucker, J ; Bagros, P ; Baudin, S ; Geslin, N</creatorcontrib><description>The development of a vaccine against hepatitis B prepared with purified and inactivated HBs Ag is described. This vaccine has been applied in patients and staff members of haemodialysis centres. Safety and efficiency of the vaccine are very satisfactory. The response of patients to immunisation was significantly lower compared to the response of the staff members. None of the volunteers who had a primary response to immunisation developed signs of clinical or biological hepatitis.</description><identifier>ISSN: 0300-8584</identifier><identifier>EISSN: 1432-1831</identifier><identifier>DOI: 10.1007/BF02121140</identifier><identifier>PMID: 723783</identifier><language>eng</language><publisher>Germany</publisher><subject>Hepatitis B - prevention & control ; Hepatitis B Antibodies - biosynthesis ; Hepatitis B Surface Antigens - immunology ; Humans ; Immunization ; Immunization, Secondary ; Renal Dialysis ; Vaccines, Attenuated - standards ; Viral Vaccines - standards</subject><ispartof>Medical microbiology and immunology, 1978-11, Vol.166 (1-4), p.109-118</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c281t-3f97338c83bc2969a62d517d66fd06577ac4e254fd3655496ffe551511f343353</citedby><cites>FETCH-LOGICAL-c281t-3f97338c83bc2969a62d517d66fd06577ac4e254fd3655496ffe551511f343353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/723783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maupas, P</creatorcontrib><creatorcontrib>Goudeau, A</creatorcontrib><creatorcontrib>Coursaget, P</creatorcontrib><creatorcontrib>Drucker, J</creatorcontrib><creatorcontrib>Bagros, P</creatorcontrib><creatorcontrib>Baudin, S</creatorcontrib><creatorcontrib>Geslin, N</creatorcontrib><title>Vaccine against hepatitis B--18 months prevention in a high risk setting</title><title>Medical microbiology and immunology</title><addtitle>Med Microbiol Immunol</addtitle><description>The development of a vaccine against hepatitis B prepared with purified and inactivated HBs Ag is described. This vaccine has been applied in patients and staff members of haemodialysis centres. Safety and efficiency of the vaccine are very satisfactory. The response of patients to immunisation was significantly lower compared to the response of the staff members. None of the volunteers who had a primary response to immunisation developed signs of clinical or biological hepatitis.</description><subject>Hepatitis B - prevention & control</subject><subject>Hepatitis B Antibodies - biosynthesis</subject><subject>Hepatitis B Surface Antigens - immunology</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization, Secondary</subject><subject>Renal Dialysis</subject><subject>Vaccines, Attenuated - standards</subject><subject>Viral Vaccines - standards</subject><issn>0300-8584</issn><issn>1432-1831</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1978</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkDtPwzAYRS3EqxQWZgZPDEgBf353pBWlSJVYgDVyHbsxNE6IXST-PUGtYLrLuWc4CF0CuQVC1N10TihQAE4O0Ag4owVoBodoRBghhRaan6KzlN4JASUpOUHHijKl2Qgt3oy1ITps1ibElHHtOpNDDglPi8GCmzbmOuGud18u5tBGHCI2uA7rGvchfeDkcg5xfY6OvNkkd7HfMXqdP7zMFsXy-fFpdr8sLNWQC-YnijFtNVtZOpETI2klQFVS-opIoZSx3FHBfcWkEHwivXdCgADwjDMm2Bhd77xd335uXcplE5J1m42Jrt2mUvHhrbQawJsdaPs2pd75sutDY_rvEkj5W638rzbAV3vrdtW46g_dZWI_WXtkaw</recordid><startdate>19781117</startdate><enddate>19781117</enddate><creator>Maupas, P</creator><creator>Goudeau, A</creator><creator>Coursaget, P</creator><creator>Drucker, J</creator><creator>Bagros, P</creator><creator>Baudin, S</creator><creator>Geslin, N</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19781117</creationdate><title>Vaccine against hepatitis B--18 months prevention in a high risk setting</title><author>Maupas, P ; Goudeau, A ; Coursaget, P ; Drucker, J ; Bagros, P ; Baudin, S ; Geslin, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c281t-3f97338c83bc2969a62d517d66fd06577ac4e254fd3655496ffe551511f343353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1978</creationdate><topic>Hepatitis B - prevention & control</topic><topic>Hepatitis B Antibodies - biosynthesis</topic><topic>Hepatitis B Surface Antigens - immunology</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization, Secondary</topic><topic>Renal Dialysis</topic><topic>Vaccines, Attenuated - standards</topic><topic>Viral Vaccines - standards</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maupas, P</creatorcontrib><creatorcontrib>Goudeau, A</creatorcontrib><creatorcontrib>Coursaget, P</creatorcontrib><creatorcontrib>Drucker, J</creatorcontrib><creatorcontrib>Bagros, P</creatorcontrib><creatorcontrib>Baudin, S</creatorcontrib><creatorcontrib>Geslin, N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medical microbiology and immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maupas, P</au><au>Goudeau, A</au><au>Coursaget, P</au><au>Drucker, J</au><au>Bagros, P</au><au>Baudin, S</au><au>Geslin, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccine against hepatitis B--18 months prevention in a high risk setting</atitle><jtitle>Medical microbiology and immunology</jtitle><addtitle>Med Microbiol Immunol</addtitle><date>1978-11-17</date><risdate>1978</risdate><volume>166</volume><issue>1-4</issue><spage>109</spage><epage>118</epage><pages>109-118</pages><issn>0300-8584</issn><eissn>1432-1831</eissn><abstract>The development of a vaccine against hepatitis B prepared with purified and inactivated HBs Ag is described. This vaccine has been applied in patients and staff members of haemodialysis centres. Safety and efficiency of the vaccine are very satisfactory. The response of patients to immunisation was significantly lower compared to the response of the staff members. None of the volunteers who had a primary response to immunisation developed signs of clinical or biological hepatitis.</abstract><cop>Germany</cop><pmid>723783</pmid><doi>10.1007/BF02121140</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-8584 |
| ispartof | Medical microbiology and immunology, 1978-11, Vol.166 (1-4), p.109-118 |
| issn | 0300-8584 1432-1831 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_74254787 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Hepatitis B - prevention & control Hepatitis B Antibodies - biosynthesis Hepatitis B Surface Antigens - immunology Humans Immunization Immunization, Secondary Renal Dialysis Vaccines, Attenuated - standards Viral Vaccines - standards |
| title | Vaccine against hepatitis B--18 months prevention in a high risk setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T02%3A16%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccine%20against%20hepatitis%20B--18%20months%20prevention%20in%20a%20high%20risk%20setting&rft.jtitle=Medical%20microbiology%20and%20immunology&rft.au=Maupas,%20P&rft.date=1978-11-17&rft.volume=166&rft.issue=1-4&rft.spage=109&rft.epage=118&rft.pages=109-118&rft.issn=0300-8584&rft.eissn=1432-1831&rft_id=info:doi/10.1007/BF02121140&rft_dat=%3Cproquest_cross%3E74254787%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=74254787&rft_id=info:pmid/723783&rfr_iscdi=true |